Clin Surg | Volume 2, Issue 1 | Research Article | Open Access

Outcome of Supraglottic Horizontal Laryngectomy

Felipe Guilherme da Silva Souza1, José Luiz Ortiz Bogado1 and Rogério Aparecido Dedivitis2*

1Department of Head and Neck Surgery, Hospital Ana Costa, Brazil
2Department of Head and Neck Surgery, Hospital das Clínicas, Brazil

*Correspondance to: Rogļæ½rio Aparecido Dedivitis 

Fulltext PDF

Abstract

Introduction: Nowadays the main objective on treatment for laryngeal carcinomas is to achieve function preservation in addition to cancer cure. The Horizontal Supraglottic Laryngectomy shows adequate outcome in both.Objective: Evaluate the outcome in a group of consecutive patients undergoing HSGL.
Methods: Between 1997 and 2016, 15 patients treated for supraglottic and base of the tongue Squamous Cell Carcinoma (SCC) with HSGL were retrospectively studied.
Results: There were 9 patients with T2 and 6 with T3 tumors. Among these, 3 patients had clinical negative neck disease. All patients underwent HSGL. Ten patients were submitted to bilateral radical neck dissection, where as 4 patients were submitted to ipsilateral radical and contra lateral neck dissection. Adjuvant radiotherapy was given to all patients. The follow up ranged from 12 to 60 months. Five-year disease-specific survival and loco regional control were 73.3%. All patients recovered a close to normal function after the treatment. A median of 16 days (7–60) was necessary to recover a close to normal diet. Decannulation took a median of 17 days (8–65). One patient died from aspiration. There was no permanent tracheostomy or total laryngectomy for functional purposes.Conclusion: HSGL remains an adequate therapeutic alternative for supraglottic SCC. Good laryngeal function recovery is the rule.

Keywords:

Laryngeal neoplasms; Laryngectomy; Carcinoma; Squamous cell; Radiotherapy; Adjuvant; Retrospective Studies

Citation:

da Silva Souza FG, Bogado JLO, Dedivitis RA. Outcome of Supraglottic Horizontal Laryngectomy. Clin Surg. 2017; 2: 1537.

Subscribe to Our Newsletter